6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Fluorescein-Based Type I Supramolecular Photosensitizer via Induction of Charge Separation by Self-Assembly

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Photosensitizers (PSs) are critical substances with considerable potential for use in non-invasive photomedicine. Type I PSs, which generate reactive radical species by electron transfer from the excited state induced via photoirradiation, attracted much attention because of their suitability for photodynamic therapy (PDT) irrespective of the oxygen concentration. However, most organic PSs are type II, which activates only oxygen, generating singlet oxygen ( 1O 2) via energy transfer from the triplet state. Here, we proposed a strategy to form type I supramolecular PSs (SPSs) utilizing the charge-separated state induced by self-assembly. This was demonstrated using a supramolecular assembly of fluorescein, which is a type II PS in the monomeric state; however, it changes to a type I SPS via self-assembly. The switching mechanism from type II to I via self-assembly was clarified using photophysical and electrochemical analyses, with the type I SPS exhibiting significant PDT effects on cancer cells. This study provides a promising approach for the development of type I PSs based on supramolecular assemblies.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: not found

          Photodynamic therapy for cancer.

          The therapeutic properties of light have been known for thousands of years, but it was only in the last century that photodynamic therapy (PDT) was developed. At present, PDT is being tested in the clinic for use in oncology--to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin. How does PDT work, and how can it be used to treat cancer and other diseases?
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Photodynamic therapy and anti-tumour immunity.

            Photodynamic therapy (PDT) uses non-toxic photosensitizers and harmless visible light in combination with oxygen to produce cytotoxic reactive oxygen species that kill malignant cells by apoptosis and/or necrosis, shut down the tumour microvasculature and stimulate the host immune system. In contrast to surgery, radiotherapy and chemotherapy that are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, invasion and infiltration of the tumour by leukocytes, and might increase the presentation of tumour-derived antigens to T cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy.

              The reactive oxygen species (ROS)-mediated mechanism is the major cause underlying the efficacy of photodynamic therapy (PDT). The PDT procedure is based on the cascade of synergistic effects between light, a photosensitizer (PS) and oxygen, which greatly favors the spatiotemporal control of the treatment. This procedure has also evoked several unresolved challenges at different levels including (i) the limited penetration depth of light, which restricts traditional PDT to superficial tumours; (ii) oxygen reliance does not allow PDT treatment of hypoxic tumours; (iii) light can complicate the phototherapeutic outcomes because of the concurrent heat generation; (iv) specific delivery of PSs to sub-cellular organelles for exerting effective toxicity remains an issue; and (v) side effects from undesirable white-light activation and self-catalysation of traditional PSs. Recent advances in nanotechnology and nanomedicine have provided new opportunities to develop ROS-generating systems through photodynamic or non-photodynamic procedures while tackling the challenges of the current PDT approaches. In this review, we summarize the current status and discuss the possible opportunities for ROS generation for cancer therapy. We hope this review will spur pre-clinical research and clinical practice for ROS-mediated tumour treatments.
                Bookmark

                Author and article information

                Journal
                JACS Au
                JACS Au
                au
                jaaucr
                JACS Au
                American Chemical Society
                2691-3704
                24 May 2022
                27 June 2022
                : 2
                : 6
                : 1472-1478
                Affiliations
                []Department of Applied Chemistry, Graduate School of Engineering, Osaka University , 2-1 Yamadaoka, Suita 565-0871, Japan
                []Frontier Research Base for Global Young Researchers, Graduate School of Engineering, Osaka University , 2-1 Yamadaoka, Suita 565-0871, Japan
                [§ ]Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University , 2-1 Yamadaoka, Suita 565-0871, Japan
                []Global Center for Medical Engineering and Informatics, Osaka University , 2-1 Yamadaoka, Suita 565-0871, Japan
                []Institute for Advanced Co-creation Studies, Osaka University , 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
                [# ]Department of Respiratory Medicine, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
                []Institute for Advanced Research, Nagoya University , Nagoya, Aichi, 464-0814, Japan
                []The Institute of Scientific and Industrial Research (ISIR), Osaka University , 8-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
                Author notes
                Author information
                https://orcid.org/0000-0002-3104-049X
                https://orcid.org/0000-0001-8328-9249
                https://orcid.org/0000-0003-3025-088X
                https://orcid.org/0000-0003-3918-0873
                https://orcid.org/0000-0003-4078-0112
                https://orcid.org/0000-0002-2336-4355
                https://orcid.org/0000-0002-5777-8580
                Article
                10.1021/jacsau.2c00243
                9241013
                35783162
                ea7dfa8f-6cf2-4df4-ab62-268afc931532
                © 2022 The Authors. Published by American Chemical Society

                Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works ( https://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 19 April 2022
                : 13 May 2022
                : 12 May 2022
                Funding
                Funded by: Takeda Science Foundation, doi 10.13039/100007449;
                Award ID: NA
                Funded by: Senri Life Science Foundation, doi 10.13039/501100008801;
                Award ID: NA
                Funded by: Kowa Life Science Foundation, doi 10.13039/501100004088;
                Award ID: NA
                Funded by: Kato Memorial Bioscience Foundation, doi 10.13039/501100004051;
                Award ID: NA
                Funded by: Japan Society for the Promotion of Science, doi 10.13039/501100001691;
                Award ID: JP18K14189
                Funded by: Japan Society for the Promotion of Science, doi 10.13039/501100001691;
                Award ID: 21K14601
                Funded by: Japan Agency for Medical Research and Development, doi 10.13039/100009619;
                Award ID: JP19lm0203014
                Funded by: Japan Agency for Medical Research and Development, doi 10.13039/100009619;
                Award ID: JP19lm0203007
                Categories
                Article
                Custom metadata
                au2c00243
                au2c00243

                supramolecular assembly,fluorescein,type i photosensitizer,reactive oxygen species (ros),charge separation

                Comments

                Comment on this article